WallStreetZenWallStreetZen

NASDAQ: REVB
Revelation Biosciences Inc Stock

$3.64-0.01 (-0.27%)
Updated Mar 1, 2024
REVB Price
$3.64
Fair Value Price
$9.75
Market Cap
$764.07k
52 Week Low
$2.40
52 Week High
$66.30
P/E
0.06x
P/B
0.09x
P/S
N/A
PEG
0x
Dividend Yield
N/A
Revenue
$0.00
Earnings
$875.06k
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.61
Operating Cash Flow
-$6M
Beta
1.19
Next Earnings
Mar 28, 2024
Ex-Dividend
N/A
Next Dividend
N/A

REVB Overview

Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-99b that is in a Phase Ib clinical trial for the prevention or treatment of chronic nasal congestion and allergic rhinitis; and REVTx-200, a nonclinical stage product for intranasal therapy. It is also involved in developing REVTx-300, a non-clinical stage product that is being developed as a potential therapy for the treatment of chronic organ disease, including chronic kidney disease and non-alcoholic steatohepatitis; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, Influenza A, Influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how REVB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

REVB ($3.64) is undervalued by 62.65% relative to our estimate of its Fair Value price of $9.75 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
REVB ($3.64) is significantly undervalued by 62.65% relative to our estimate of its Fair Value price of $9.75 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
REVB ($3.64) is trading below... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more REVB due diligence checks available for Premium users.

Be the first to know about important REVB news, forecast changes, insider trades & much more!

REVB News

Valuation

REVB fair value

Fair Value of REVB stock based on Discounted Cash Flow (DCF)
Price
$3.64
Fair Value
$9.75
Undervalued by
62.65%
REVB ($3.64) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
REVB ($3.64) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
REVB ($3.64) is trading below... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

REVB price to earnings (PE)

For valuing profitable companies with steady earnings
Company
0.06x
Industry
15.19x
Market
36.17x
REVB is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
REVB is good value based... subscribe to Premium to read more.
P/E vs Market Valuation

REVB price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.09x
Industry
6.18x
REVB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

REVB price to earnings growth (PEG)

For valuing profitable companies with growth potential
REVB is good value based... subscribe to Premium to read more.
PEG Value Valuation

REVB's financial health

Profit margin

Revenue
$0.0
Net Income
-$2.6M
Profit Margin
0%
REVB's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$14.2M
Liabilities
$5.4M
Debt to equity
0.61
REVB's short-term assets ($14.15M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
REVB's short-term assets ($14.15M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
REVB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$1.7M
Investing
$0.0
Financing
$0.0
REVB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

REVB vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
REVB$764.07k-0.27%0.06x0.09x
CMND$965.67k+3.25%-0.04x0.98x
CYTO$966.41k+29.26%-0.01x-0.47x
NBY$992.45k+4.11%-0.02x0.14x
TCBP$438.52k+5.56%-0.02x0.18x

Revelation Biosciences Stock FAQ

What is Revelation Biosciences's quote symbol?

(NASDAQ: REVB) Revelation Biosciences trades on the NASDAQ under the ticker symbol REVB. Revelation Biosciences stock quotes can also be displayed as NASDAQ: REVB.

If you're new to stock investing, here's how to buy Revelation Biosciences stock.

What is the 52 week high and low for Revelation Biosciences (NASDAQ: REVB)?

(NASDAQ: REVB) Revelation Biosciences's 52-week high was $66.30, and its 52-week low was $2.40. It is currently -94.51% from its 52-week high and 51.67% from its 52-week low.

How much is Revelation Biosciences stock worth today?

(NASDAQ: REVB) Revelation Biosciences currently has 209,910 outstanding shares. With Revelation Biosciences stock trading at $3.64 per share, the total value of Revelation Biosciences stock (market capitalization) is $764.07k.

Revelation Biosciences stock was originally listed at a price of $10,447.50 in Oct 8, 2020. If you had invested in Revelation Biosciences stock at $10,447.50, your return over the last 3 years would have been -99.97%, for an annualized return of -92.96% (not including any dividends or dividend reinvestments).

How much is Revelation Biosciences's stock price per share?

(NASDAQ: REVB) Revelation Biosciences stock price per share is $3.64 today (as of Mar 1, 2024).

What is Revelation Biosciences's Market Cap?

(NASDAQ: REVB) Revelation Biosciences's market cap is $764.07k, as of Mar 5, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Revelation Biosciences's market cap is calculated by multiplying REVB's current stock price of $3.64 by REVB's total outstanding shares of 209,910.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.